A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.

Inclusion Criteria: * A male or female subject 15 years of age or older at the time of the study entry. * Written informed consent obtained from the subject/ from the parent or guardian of the subject. * Seronegative for anti-HBs antibodies, anti-HBc antibodies and for HBsAg at screening. * Pre-dialysis patients, peritoneal dialysis patients or haemodialysis patients. * Non-childbearing potential female Exclusion Criteria: * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Use of any registered vaccine within 7 days before the first dose of study vaccine. * Previous vaccination against hepatitis B (whether or not the subject responded to the vaccine). * History of hepatitis B infection. * Known exposure to hepatitis B virus within 6 months. * Use of immunoglobulins within six months preceding the first study vaccination. * Immunosuppression caused by the administration of parenteral steroids or chemotherapy (oral steroids are allowed). * Any confirmed or suspected human immunodeficiency virus (HIV) infection. * A family history of congenital or hereditary immunodeficiency. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral/ axillary temperature \< 37.5°C (or 37 °C in Czech Republic). * Oral/axillary temperature superior or equal to 37.5°C (or 37 °C in Czech Republic). * Pregnant or lactating female